Irvine_Growth and bone biomarkers_Supplementary material_JAAD 2026

Published: 30 June 2026| Version 1 | DOI: 10.17632/pvc6pmwx9z.1
Contributors:
Alan Irvine, Amy Paller, Elaine Siegfried, Michael Cork, Lisa Beck, Lawrence Eichenfield, Lisa Swanson, Sara Hamon, Julie Horowitz, Annamaria Farrell, Sarah Hatsell, Annie Zhang, Ashish Bansal, Xiaojun You, Zhen Chen, Stephane Levy, Sonya Cyr

Description

Supplementary material to the article titled "Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study" Contents: Page Plain Language Summary 2 Laboratory measurements 4 Supplementary Figure 1. Atopic dermatitis. Mean BALP over time to week 52 in patients with and without asthma comorbidity. 5 Supplementary Figure 2. Atopic dermatitis. A, Osteocalcin (OC); B, procollagen type 1 N-terminal propeptide (P1NP); C, insulin-like growth factor 1 (IGF-1); D, C-terminal crosslinking telopeptide of type-1 collagen (CTX-1) over time to week 52. 6

Files

Categories

Pediatrics, Biologic Therapy, Atopic Dermatitis, Bone Growth

Funders

Licence